In short: Chronic kidney disease causes heart disease through several linked mechanisms — sodium and volume overload, neurohormonal activation, mineral-bone disorder with vascular calcification, uremic toxins with inflammation, anemia, and albuminuria as a marker of vascular injury. Together they make the kidney an early driver of cardiovascular disease, not merely a bystander, which is why kidney measures independently predict cardiovascular events.
The kidney as an early driver
Cardiovascular disease is the leading cause of death in people with chronic kidney disease, and the risk begins to rise long before kidney failure. Even modest reductions in eGFR and small increases in urine albumin independently predict heart attacks, strokes, heart failure, and cardiovascular death. Understanding how the kidney injures the heart explains why treating kidney disease early is also cardiovascular prevention.
Six mechanisms linking kidney to heart
Sodium and volume overload
Failing kidneys retain sodium and water. The resulting volume expansion raises blood pressure and preload, driving left ventricular hypertrophy and, ultimately, heart failure.
Neurohormonal activation
CKD chronically activates the renin–angiotensin–aldosterone system and the sympathetic nervous system. Beyond raising blood pressure, this promotes cardiac fibrosis and adverse remodeling.
Mineral-bone disorder and vascular calcification
As kidneys fail, phosphate is retained and FGF23 rises. The mineral imbalance accelerates calcification of the arterial wall and heart valves, stiffening vessels and increasing cardiac workload.
Uremic toxins, inflammation, and oxidative stress
Retained uremic solutes together with chronic inflammation and oxidative stress injure the endothelium and accelerate atherosclerosis, giving patients with CKD a distinctly high atherosclerotic burden.
Anemia of CKD
Reduced kidney erythropoietin lowers hemoglobin. Chronic anemia increases cardiac output demand and contributes to left ventricular hypertrophy and heart-failure progression.
Albuminuria as a vascular signal
Urine albumin is more than a kidney marker — it reflects systemic endothelial dysfunction. That is why albuminuria independently predicts cardiovascular events, and why it refines the PREVENT cardiovascular risk estimate.
What the kidney does to the heart
Clinically, these mechanisms surface as heart failure across the ejection-fraction spectrum, accelerated atherosclerotic disease, atrial fibrillation, and resistant hypertension. Recognizing CKD as an early cardiovascular risk driver is the reason organ-protective therapy is started on kidney indications, before overt heart disease appears.
See the mechanisms interactivelyWalk through each kidney-to-heart pathway and its consequences in the CKM Explorer.Open the CKM Explorer →Frequently asked questions
Why does chronic kidney disease cause heart disease?
CKD drives heart disease through linked mechanisms: sodium and volume overload raising blood pressure and preload; neurohormonal (RAAS and sympathetic) activation causing fibrosis and remodeling; mineral-bone disorder with vascular calcification; uremic toxins, inflammation, and oxidative stress accelerating atherosclerosis; anemia increasing cardiac workload; and albuminuria signalling systemic endothelial dysfunction.
Is the kidney a cardiovascular risk factor?
Yes. Reduced eGFR and increased albuminuria independently predict cardiovascular events even before kidney failure, so the kidney is considered an early driver of cardiovascular disease rather than a late complication. Both measures are included in the AHA PREVENT risk equations.
How does albuminuria relate to heart disease?
Urine albumin reflects systemic endothelial dysfunction, not just kidney damage, which is why higher albuminuria independently predicts cardiovascular events and refines the PREVENT cardiovascular risk estimate.
What cardiovascular conditions does CKD lead to?
CKD is associated with heart failure across the ejection-fraction spectrum, accelerated atherosclerotic disease, atrial fibrillation, and resistant hypertension.
References
- Ndumele CE, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023. doi:10.1161/CIR.0000000000001184
- Khan SS, et al. Development and Validation of the American Heart Association’s PREVENT Equations. Circulation. 2024. doi:10.1161/CIRCULATIONAHA.123.067626
- KDIGO CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024. doi:10.1016/j.kint.2023.10.018
Educational use only. This page explains concepts for health professionals, trainees, and students. It is not medical advice and does not calculate an individual patient’s risk.